OKYO Pharma (OKYO) has received $1.4M in non-dilutive funding. The company said, “This significant financial funding strengthens the Company’s ability to advance its innovative pipeline ...

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company engaged in developing treatments for ocular conditions, has reported insider share purchases on the NASDAQ. The company's CEO, ...

LONDON and NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...

OKYO Pharma's CEO and Executive Chairman purchased shares, increasing their stake as the company develops treatments for eye conditions. OKYO Pharma Limited, a clinical-stage biopharmaceutical ...

OKYO Pharma (OKYO) has been notified that the CEO Gary Jacob has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of $1.04 per share. The company said, “We have also been ...

LONDON - OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company with a market capitalization of $35.05 million focused on developing treatments for neuropathic corneal pain (NCP) and dry eye ...